On Tuesday,Shares of Oasis Petroleum Inc. (NYSE:OAS), SUBTRACT -2.59% and closed at $11.29 in the last trading session. The last trading range of the stock ranges between $11.23 and $11.79. Oasis Petroleum Inc. (“Oasis” or “the Company”) (OAS) declared recently the exercise by the underwriters of the full over-allotment option of $25.0 million aggregate principal amount of its 2.625% senior unsecured convertible notes due 2023 (the “Notes”). The over-allotment option was granted to the underwriters by the Company in connection with the formerly consummated offering of $275 million aggregate principal amount of the Notes. Settlement of the sale of additional Notes is expected to occur on September 30, 2016, subject to customary closing conditions. Oasis intends to use the net proceeds from the sale of additional Notes for general corporate purposes, which may include redemptions or repurchases of its existing senior notes.
Diamond Offshore Drilling Inc (NYSE:DO), DROPPED -4.60% and closed at $16.60 in the last trading session. The last trading range of the stock ranges between $16.54 and $17.63. The company’s Market capitalization is $2.25 Billion with the total Outstanding Shares of 137.17 million.S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective after the close of trading on Friday, September 30:
Coty Inc. (COTY) will replace Diamond Offshore Drilling Inc. (DO) in the S&P 500, and Diamond Offshore Drilling will replace Polycom Inc. (PLCM) in the S&P MidCap 400. Siris Capital Group attained Polycom in a deal accomplished recently. Diamond Offshore Drilling is ranked at the bottom of the S&P 500 and has a market capitalization more representative of the mid-cap market space.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), jumped 4.14% and closed at $7.05 in the last trading session. The last trading range of the stock ranges between $6.86 and $7.75. During the 52-week trading session the minimum price at which share price traded, registered at $3.61 and reached to max level of $8.37. Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The companys primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted PET imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration resistant prostate cancer; PSMA antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; and EXINI Bone BSI, an analytical tool for analysis of bone scan index from bone scintigraphy images. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, it develops Relistor-oral that has accomplished Phase III testing for the treatment of OIC; and PRO 140, which is in Phase III testing for HIV treatment.